LILAC pilot study : effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapy
Fiche du document
24 janvier 2023
- handle: 10670/1.ckx6t4
- doi: 10.1016/j.ebiom.2021.103270
Ce document est mis à disposition selon les termes de la Licence Creative Commons Attribution - Pas d’utilisation commerciale - Pas de Modification 4.0 International. / This work is licensed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License. , https://creativecommons.org/licenses/by-nc-nd/4.0/deed.fr
Mots-clés
Metformin ART HIV reservoirs Th17 MTORSujets proches
Dimethylguanylguanidine DimethylbiguanidineCiter ce document
Delphine Planas et al., « LILAC pilot study : effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapy », Papyrus : le dépôt institutionnel de l'Université de Montréal, ID : 10.1016/j.ebiom.2021.103270
Métriques
Partage / Export
Résumé
Background: Chronic inflammation and residual HIV transcription persist in people living with HIV (PLWH) receiving antiretroviral therapy (ART), thus increasing the risk of developing non-AIDS co-morbidities. The mechanistic target of rapamycin (mTOR) is a key regulator of cellular metabolism and HIV transcription, and therefore represents an interesting novel therapeutic target. Methods: The LILAC pilot clinical trial, performed on non-diabetic ART-treated PLWH with CD4+ /CD8+ T-cell ratios